PubMed Health⌕ Search

Biomedical subjects

U B Seiffert

Publications and source records attributed to U B Seiffert.

32 records · Page 2Linked to original sources
PubMed1980

Alkaline phosphatase bone isoenzyme activity in serum in various degrees of micromorphometrically assessed renal osteopathy.

Alkaline phosphatase bone isoenzyme activity in serum correlates significantly to micromorphometrically assessed parameters of bone apposition as well as resorption. Though as both processes appear to be coupled in renal osteopathy, bone isoenzyme activity seems to reflect mainly hyperosteoid states. The detection of abnormal findings is impressively better by bone isoenzyme analysis as compared with total alkaline phosphatase activity; pathological values are found even at the initial phase of osteopathy in early renal failure. The determination of alkaline phosphatase bone isoenzyme activity in serum is a sensitive and reliable diagnostic tool in assessing the beginning and degree of metabolic bone disease.

Adult↗
PubMed1977

Quantitative alkaline phosphatase isoenzyme determination by electrophoresis on cellulose acetate membranes.

We present a new method for quantitative determination of alkaline phosphatase isoenzymes. This method consists of electrophoretic separation on cellulose acetate membranes, special fixation technique to avoid elution and diffusion of enzyme protein during incubation, specific staining, and quantitative evaluation by densitometric measurement. We highly recommend the precedure for routine clinical laboratory use. In all normal individuals we observe two isoenzymes of hepatic origin and one isoenzyme each of osseous, intestinal, and biliary origin. Quantitative normal values are presented. Precision of the method is calculated, the CV being less than 10%. The exactness of densitometric quantification is proved by comparison with kinetic assay of alkaline phosphatase isoenzymes by use of an elution method. Clinical implications of alkaline phosphatase isoenzymograms are reported and discussed in detail.

Alkaline Phosphatase↗
PubMedDate not supplied

Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.

The monoclonal antibody pyruvate kinase type tumor M2 (TUM2-PK) has been shown to have a high binding capacity to pancreatic cancer. In present study TUM2-PK serum levels were measured in pancreatic cancer and compared with the reference tumor markers CA19-9, CA50, CA72-4 and CEA. Overall 100 patients were included in this study, 64 patients had a histologically confirmed pancreatic carcinoma, 36 patients gastrointestinal cancer (stomach, colon), 666 healthy volunteers served as controls. Measurements were done by enzymimmunoassay. For the healthy blood donors a cut-off value of 22.5 U/ml was evaluated, which corresponds to 95% specificity. In patients with pancreatic cancer the sensitivities of TUM2-PK, CA19-9, CEA, CA72-4 and CA50 were 71%; 68%, 37%, 49% and 63.4% respectively. Linear regression analysis indicated that there was a positive correlation (r = 0.79). According to the results of our study TUM2-PK has comparable sensitivity but higher specificity than the reference tumor marker CA19-9.

Biomarkers, Tumor↗
PubMedDate not supplied

Diagnostic value of skeletal AP and PSA with respect to skeletal scintigram in patients with prostatic disease.

The aim of this study was to compare the diagnostic value of skeletal AP and PSA with the skeletal scintigram in patients with prostatic cancer. PSA and skeletal AP were measured by Tandem-R-Ostase Assay (IRMA) and Tandem-R-PSA-Assay. 64 patients with prostatic cancer, 20 of them in stage D2 were involved. Patients with a prostatic cancer and bone metastases show remarkable increased skeletal AP concentration with a median concentration of 50ng/ml SAP and 95 ng/ml PSA. Patients without bone metastases have a lower median concentration of SAP at 10 ng/ml and PSA concentration of 40 ng/ml which is within the normal range. Six out of 20 patients at stage D2 showed a significant increase of SAP concentration and even of PSA before bone metastases were seen by skeletal scintigraphy. We conclude when skeletal metastases are assumed in patients with prostatic cancer, a combination of skeletal scintigramm and measurement of SAP seem to be of advantage to recognize patients with bone metastases earlier.

Alkaline Phosphatase↗